Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of NBI-827104 in essential tremor
2020-006012-24Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NBI-827104 in essential tremor (ET) (2 arms), sponsored by Neurocrine Biosciences. Started Mar 2021; status: completed.
02
Drugs
NBI-827104
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on 2020-006012-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006012-24.